How many employees does 4D Molecular Therapeutics, Inc. have?

4D Molecular Therapeutics, Inc. reported 196 employees for the fiscal year ending Dec 2025, in the annual report it filed on March 18, 2026. That is down 13.7% from a year earlier.

What is 4D Molecular Therapeutics, Inc.'s revenue per employee?

4D Molecular Therapeutics, Inc. brought in $85.2M of revenue in fiscal Dec 2025, which is $435K per employee. That ranks 58 of 108 companies we track in Biotechnology, where the median is $459K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

4D Molecular Therapeutics, Inc. employees and revenue per employee

FDMT · Biotechnology · $697M market cap

4D Molecular Therapeutics, Inc. had 196 employees at the end of fiscal Dec 2025, down 13.7% from a year earlier. Revenue for the year was $85.2M, up 230194.6% from a year earlier, or $435K per employee. Revenue held up or grew while headcount stayed flat or fell.

Employees

196

-13.7% YoY

Revenue

$85.2M

+230194.6% YoY

Revenue / employee

$435K

Peer median $459K

Rank in industry

58 of 108

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2020

Hover a year for the numbers.

FDMT employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2025	196	$85.2M	$435K	-13.7%	+230194.6%
Dec 2024	227	$37,000	$163	+54.4%	-99.8%
Dec 2023	147	$20.7M	$141K	+5.0%	+562.3%
Dec 2022	140	$3.1M	$22K	+12.9%	-82.7%
Dec 2021	124	$18.0M	$145K	+49.4%	+32.5%
Dec 2020	83	$13.6M	$164K	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

4D Molecular Therapeutics, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
ASMB Assembly Biosciences, Inc.	73	$72.3M	$990K	Leaner
AMLX Amylyx Pharmaceuticals, Inc.	123	$87.4M	$710K	Contracting
FDMT 4D Molecular Therapeutics, Inc.	196	$85.2M	$435K	Leaner
ZYME Zymeworks Inc.	264	$106M	$401K	Leaner
VRDN Viridian Therapeutics, Inc.	252	$70.8M	$281K	Efficient growth
NRIX Nurix Therapeutics, Inc.	317	$84.0M	$265K	Efficient growth
MGTX MeiraGTx Holdings plc	400	$81.4M	$203K	Efficient growth
VIR Vir Biotechnology, Inc.	367	$68.6M	$187K	Contracting
CYTK Cytokinetics, Incorporated	673	$88.0M	$131K	Efficient growth

Every Healthcare company

Questions about 4D Molecular Therapeutics, Inc.

How many employees does 4D Molecular Therapeutics, Inc. have?: 4D Molecular Therapeutics, Inc. reported 196 employees for the fiscal year ending Dec 2025, in the annual report it filed on March 18, 2026. That is down 13.7% from a year earlier.
What is 4D Molecular Therapeutics, Inc.'s revenue per employee?: 4D Molecular Therapeutics, Inc. brought in $85.2M of revenue in fiscal Dec 2025, which is $435K per employee. That ranks 58 of 108 companies we track in Biotechnology, where the median is $459K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare FDMT with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in 4D Molecular Therapeutics, Inc.'s annual reports (Form 10-K), latest filed March 18, 2026. This is data, not a recommendation to buy or sell FDMT.